AZ is hoping that Fasenra (benralizumab) could join rival drugs from Sanofi/Regeneron and GlaxoSmithKline as ... the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.

They also need to be having at least four severe asthma attacks per year and either have not responded to, or be unable to tolerate, other biologic drugs like GlaxoSmithKline's Nucala (mepolizumab).

TD Cowen analyst Steve Scala maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of $45.00. The ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Though GSK is definitely not the best large-cap drugmaker to have in one's portfolio, we believe there is potential for its ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review, data from the MATINEE study ...

In addition, GSK said its Blenrep drug has been approved for priority review in China to treat sufferers of myeloma, a bone marrow cancer. The regulatory submission is supported by phase III ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

London open The FTSE 100 is expected to open eight points higher on Monday, having closed down 0.49% on Friday at 8,308.61.

It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...